Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
Conditions:   Myelodysplastic Syndromes;   Ferroptosis Intervention:   Biological: Biological sampling Sponsor:   University Hospital, Bordeaux Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2023 Category: Research Source Type: clinical trials

The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
Condition:   Lower Risk MDS Per IPSS-R Intervention:   Drug: Luspatercept Sponsors:   Institute of Hematology & Blood Diseases Hospital;   Beijing Health Alliance Charitable Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2023 Category: Research Source Type: clinical trials

Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
Conditions:   Myelodysplastic Syndromes;   Ferroptosis Intervention:   Biological: Biological sampling Sponsor:   University Hospital, Bordeaux Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2023 Category: Research Source Type: clinical trials

The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
Condition:   Lower Risk MDS Per IPSS-R Intervention:   Drug: Luspatercept Sponsors:   Institute of Hematology & Blood Diseases Hospital;   Beijing Health Alliance Charitable Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2023 Category: Research Source Type: clinical trials

Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
Conditions:   Myelodysplastic Syndromes;   Ferroptosis Intervention:   Biological: Biological sampling Sponsor:   University Hospital, Bordeaux Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2023 Category: Research Source Type: clinical trials